Current status and progress of prepandemic and pandemic influenza vaccine development

References

• Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg. Infect. Dis.12(1), 15–22 (2006).
   PubMed Web of Science ®Google Scholar
• Longini IM Jr, Nizam A, Xu S et al. Containing pandemic influenza at the source. Science309(5737), 1083–1087 (2005).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DA, Cauchemez S et al. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature437(7056), 209–214 (2005).
   PubMed Web of Science ®Google Scholar
• Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature442(7101), 448–452 (2006).
   PubMed Web of Science ®Google Scholar
• Halloran ME, Ferguson NM, Eubank S et al. Modeling targeted layered containment of an influenza pandemic in the United States. Proc. Natl Acad. Sci. USA105(12), 4639–4644 (2008).
   PubMed Web of Science ®Google Scholar
• Webster RG, Govorkova EA. H5N1 influenza – continuing evolution and spread. N. Engl. J. Med.355(21), 2174–2177 (2006).
   PubMed Web of Science ®Google Scholar
• Subbarao K, Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat. Rev. Immunol.7(4), 267–278 (2007).
   PubMed Web of Science ®Google Scholar
• Osterhaus AD. Pre- or post-pandemic influenza vaccine? Vaccine25(27), 4983–4984 (2007).
   PubMed Web of Science ®Google Scholar
• Wood JM. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine20(Suppl. 5), B40–B44 (2002).
   PubMed Web of Science ®Google Scholar
• Wood JM, Nicholson KG, Stephenson I et al. Experience with the clinical development of influenza vaccines for potential pandemics. Med. Microbiol. Immunol.191(3–4), 197–201 (2002).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Gust I, Pervikov Y, Kieny MP. Development of vaccines against influenza H5. Lancet Infect. Dis.6(8), 458–460 (2006).
   PubMed Web of Science ®Google Scholar
• Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity24(1), 5–9 (2006).
   PubMed Web of Science ®Google Scholar
• Stephenson I. H5N1 vaccines: how prepared are we for a pandemic? Lancet368(9540), 965–966 (2006).
   PubMed Web of Science ®Google Scholar
• Fedson DS. Vaccine development for an imminent pandemic: why we should worry, what we must do. Hum. Vaccin.2(1), 38–42 (2006).
   PubMed Web of Science ®Google Scholar
• Poland GA, Jacobson RM, Targonski PV. Avian and pandemic influenza: an overview. Vaccine25(16), 3057–3061 (2007).
   PubMed Web of Science ®Google Scholar
• El Sahly HM, Keitel WA. Pandemic H5N1 influenza vaccine development: an update. Expert Rev. Vaccines7(2), 241–247 (2008).
   PubMed Web of Science ®Google Scholar
• Poland GA, Sambhara S. Vaccines against influenza A (H5N1): evidence of progress. J. Infect. Dis.198(5), 629–631 (2008).
   PubMed Web of Science ®Google Scholar
• Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathog.3(3), e40 (2007).
   PubMed Web of Science ®Google Scholar
• Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect. Dis.8(10), 650–658 (2008).
   PubMed Web of Science ®Google Scholar
• Kieny MP, Subbarao K. The pandemic influenza vaccine challenge. Vaccine26S(Suppl. 4), D3–D4 (2008).
   Google Scholar
• Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet371(9622), 1464–1475 (2008).
   PubMed Web of Science ®Google Scholar
• Peiris JS, de Jong MD, Guan Y. Avian influenza virus (H5N1): a threat to human health. Clin. Microbiol. Rev.20(2), 243–267 (2007).
   PubMed Web of Science ®Google Scholar
• Wood JM, Robertson JS. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol.2(10), 842–847 (2004).
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet357(9272), 1937–1943 (2001).
   PubMed Web of Science ®Google Scholar
• Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol.37(4), 937–943 (1999).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine21(15), 1687–1693 (2003).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res.103(1–2), 91–95 (2004).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Das RG, Wood JM, Katz JM. Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine25(20), 4056–4063 (2007).
   PubMed Web of Science ®Google Scholar
• Girard MP, Osterhaus A, Pervikov Y, Palkonyay L, Kieny MP. Report of the third meeting on “influenza vaccines that induce broad spectrum and long-lasting immune responses”, World Health Organization, Geneva, Switzerland, 3–4 December 2007. Vaccine26(20), 2443–2450 (2008).
   PubMed Web of Science ®Google Scholar
• Kistner O, Howard MK, Spruth M et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine25(32), 6028–6036 (2007).
   PubMed Web of Science ®Google Scholar
• Kistner O, Barrett PN, Mundt W, Reiter M, Schober-Bendixen S, Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine16(9–10), 960–968 (1998).
   PubMed Web of Science ®Google Scholar
• Ehrlich HJ, Muller M, Oh HM et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N. Engl. J. Med.358(24), 2573–2584 (2008).
   PubMed Web of Science ®Google Scholar
• Barrett N. Vero cell technology and H5N1 influenza vaccines – a unique combination. Presented at: 13th International Congress on Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008.
   Google Scholar
• Kistner O, Howard MK, Sabarth N et al. Induction of cross-clade anti-H5N1 immune responses in mice, guinea pigs and ferrets by Vero cell-derived H5N1 whole virus candidate vaccine. Presented at: Third European Influenza Conference – ESWI. Vilamoura, Portugal, 14–17 September 2008.
   Google Scholar
• Nolan TM, Richmond PC, Skeljo MV et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine26(33), 4160–4167 (2008).
   PubMed Web of Science ®Google Scholar
• Nolan T, Richmond PC, Formica NT et al. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine26(50), 6383–6391 (2008).
   PubMed Web of Science ®Google Scholar
• Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res.103(1–2), 163–171 (2004).
   PubMed Web of Science ®Google Scholar
• Hehme N, Engelmann H, Kunzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med. Microbiol. Immunol.191(3–4), 203–208 (2002).
   PubMed Web of Science ®Google Scholar
• Hehme N, Kuhn A, Mueller M et al. Whole virus alum-adjuvanted pandemic vaccine: safety and immunogenicity data on a vaccine formulated with H5N1. Presented at: International Conference on Influenza Vaccines for the World – IVW2006. Vienna, Austria, 18–20 October 2006.
   Google Scholar
• Leroux-Roels I, Borkowski A, Vanwolleghem T et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet370(9587), 580–589 (2007).
   PubMed Web of Science ®Google Scholar
• Rumke HC, Bayas JM, de Juanes JR et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a Phase III safety trial. Vaccine26(19), 2378–2388 (2008).
   PubMed Web of Science ®Google Scholar
• Chu D-S, Dramé M, Hwang S-J. Safety and immunogenicity of an AS adjuvanted H5N1 pepandemic influenza vaccine: a Phase III study in a large population of Asian adults. Presented at: Xth International Symposium on Respiratory Viral Infections. Singapore, 28 February–1 March 2008 (Abstract).
   Google Scholar
• Ballester A, Garcés-Sanches M, Planelles Cantinaro M. Pediatric safety evaluation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 6–9 years. A Phase II study. Presented at: 26th Annual Meeting of the European Society for Pediatric Infectious Diseases. Graz, Austria, 13–17 May 2008.
   Google Scholar
• Ballester A, Garcés-Sanches M, Planelles Cantinaro M et al. Pediatric safety evalation of an AS-adjuvanted H5N1 prepandemic candidate vaccine in children aged 3–9 years. A Phase II study. Presented at: 13th International Congress of Infectious Diseases. Kuala Lumpur, Malaysia, 19–22 June 2008.
   Google Scholar
• Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs22(5), 279–292 (2008).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Bernhard R, Gerard P, Drame M, Hanon E, Leroux-Roels G. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE3(2), e1665 (2008).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I, Moris P, Dramé M et al. Persistent immune response against clade 1 and 2 H5N1 strains induced by an AS adjuvanted H5N1 clade 1 candidate prepandemic influenza vaccine. Presented at: International Conference on Avian Influenza. Bangkok, Thailand, 23–25 January 2008.
   Google Scholar
• Moris P, Leroux-Roels I, Dramé M et al. Heterologous cell-mediated immunity priming using adjuvanted H5N1 vaccine. Presented at: IXth International Symposium on Respiratory Viral Infections. Hong Kong, China, 3–6 March 2007.
   Google Scholar
• Zitzow LA, Rowe T, Morken T, Shieh WJ, Zaki S, Katz JM. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol.76(9), 4420–4429 (2002).
   PubMed Web of Science ®Google Scholar
• Govorkova EA, Rehg JE, Krauss S et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol.79(4), 2191–2198 (2005).
   PubMed Web of Science ®Google Scholar
• Hampson AW. Ferrets and the challenges of H5N1 vaccine formulation. J. Infect. Dis.194(2), 143–145 (2006).
   PubMed Web of Science ®Google Scholar
• Baras B, Stittelaar K, Simon JH. Immunization with low dose adjuvanted split H5N1 pandemic vaccine protects ferrets against homologous challenge. Presented at: IXth International Symposium on Respiratory Viral Infections. Hong Kong, China, 3–6 March, 2007.
   Google Scholar
• Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE3(1), e1401 (2008).
   PubMed Web of Science ®Google Scholar
• Vajo Z, Kosa L, Visontay I, Jankovics M, Jankovics I. Inactivated whole virus influenza A (H5N1) vaccine. Emerg. Infect. Dis.13(5), 807–808 (2007).
   PubMed Web of Science ®Google Scholar
• Vajo Z, Kosa L, Szilvasy I et al. Safety and immunogenicity of a prepandemic influenza A (H5N1) vaccine in children. Pediatr. Infect. Dis. J.27(12), 1052–1056 (2008).
   PubMed Web of Science ®Google Scholar
• Fazekas G, Martosne-Mendi R, Jankovics I, Szilvasy I, Vajo Z. Cross-reactive immunity in adult and elderly patients against clade 2 influenza A H5N1 virus strains induced by Fluval, a reverse genetic-derived adjuvanted H5N1 clade 1 prototype pandemic influenza vaccine. Clin. Vaccine Immunol. (Epub ahead of print) (2008).
   PubMedGoogle Scholar
• Martin JT. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals25(2), 209–213 (1997).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J. Infect. Dis.191(8), 1210–1215 (2005).
   PubMed Web of Science ®Google Scholar
• Atmar RL, Keitel WA, Patel SM et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin. Infect. Dis.43(9), 1135–1142 (2006).
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Edwards KM, Dekker CL et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis.197(5), 667–675 (2008).
   PubMed Web of Science ®Google Scholar
• Stephenson I, Nicholson KG, Hoschler K et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N. Engl. J. Med.359(15), 1631–1633 (2008).
   PubMed Web of Science ®Google Scholar
• Podda A, Del Giudice G. MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile. Expert Rev. Vaccines2(2), 197–203 (2003).
   PubMedGoogle Scholar
• O’Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev. Vaccines6(5), 699–710 (2007).
   PubMed Web of Science ®Google Scholar
• Barbera J P, Vidal DG. MF59-adjuvanted subunit influenza vaccine: an improved interpandemic influenza vaccine for vulnerable populations. Expert Rev. Vaccines6(5), 659–665 (2007).
   PubMed Web of Science ®Google Scholar
• Borgogni E, Castellino F, Galli G et al. MF59-adjuvanted H5N1 subunit vaccine induces a high frequency of Th1 effector/memory CD4 T-cells which persist over time. Presented at: 3rd European Influenza Conference. Vilamoura, Portugal, 14–17 September 2008.
   Google Scholar
• Banzhoff A, Gasparini R, Laghi-Pasini F et al. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PLoS ONE4(2), e4384 (2009).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med.354(13), 1343–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet367(9523), 1657–1664 (2006).
   PubMed Web of Science ®Google Scholar
• Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis.198(5), 642–649 (2008).
   PubMed Web of Science ®Google Scholar
• Lina B, Fletcher MA, Valette M, Saliou P, Aymard M. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European community for immunogenicity, in children, adults and the elderly. Biologicals28(2), 95–103 (2000).
   PubMed Web of Science ®Google Scholar
• Höschler K, Gopal R, Andrews N et al. Cross-neutralisaton of antibodies elicited by an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healty adults against H5N1 clade 2 strains. Influenza Other Respir. Viruses1(5–6), 199–206 (2008).
   Web of Science ®Google Scholar
• Chotpitayasunondh T, Thisyakorn U, Pancharoen C, Pepin S, Nougarede N. Safety, humoral and cell mediated immune responses to two formulations of an inactivated, split virion influenza A/H5N1 vaccine in children. PLoS ONE3(12), e4028 (2008).
   PubMed Web of Science ®Google Scholar
• Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J. Virol.82(5), 2565–2569 (2008).
   PubMed Web of Science ®Google Scholar
• Bigger J, Ruat C, Vasconcelos D, Legastelois I, Stark G, Caillet C. A new adjuvanted low-dose candidate pandemic influenza A(H5N1) vaccine protects ferrets against homologous clade 1 viral challenge and induces clade 2 cross-reactive antibodies. Presented at: International Conference on Avian Influenza. Bangkok, Thailand, 23–25 January 2008.
   Google Scholar
• Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a Phase I randomised controlled trial. Lancet368(9540), 991–997 (2006).
   PubMed Web of Science ®Google Scholar
• Lin JT, Li CG, Wang X et al. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine. J. Infect. Dis.199(2), 184–187 (2009).
   PubMed Web of Science ®Google Scholar
• Jin R, Lv Z, Chen Q et al. Safety and immunogenicity of H5N1 influenza vaccine based on baculovirus surface display system of Bombyx mori. PLoS ONE3(12), e3933 (2008).
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Schiff GM, Hayden FG et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA297(14), 1577–1582 (2007).
   PubMed Web of Science ®Google Scholar
• Gerhard W, Mozdzanowska K, Zharikova D. Prospects for universal influenza virus vaccine. Emerg. Infect. Dis.12(4), 569–574 (2006).
   PubMed Web of Science ®Google Scholar
• Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med.5(10), 1157–1163 (1999).
   PubMed Web of Science ®Google Scholar